Replies to post #117278 on Biotech Values

[DewDiligence]

Bridge, what do you see as the peak worldwide sales for this product if the safety and efficacy data continue to be strong? I’m asking you because you probably know more about medical devices than anyone who posts here. T.i.a.

[DewDiligence]

Reva Medical (RVA.AX) plans trial of bioabsorbable stent:

http://finance.yahoo.com/news/REVA-Receives-Approval-for-pz-781204715.html?x=0&.v=1

ABT is the leader in this field (#msg-61503095).

[DewDiligence]

Nothing about BSX’s 2006 acquisition of Guidant has worked out well for BSX and that includes income taxes:

http://www.sec.gov/Archives/edgar/data/885725/000088572511000059/form8-kirsnoticeofdeficien.htm

On December 1, 2011, we received a Notice of Deficiency from the Internal Revenue Service (IRS) claiming that we owe additional net taxes of $581 million, plus interest and penalties, based on an audit of the 2004, 2005 and 2006 tax years of Guidant Corporation and its subsidiaries as they existed in that time period.

[DewDiligence]

ABT launches Absorb bioresorbable stent in 30 countries (but not US):

http://finance.yahoo.com/news/abbott-announces-international-launch-absorb-120000494.html

This is an amazing product that disappears completely when its work is done. Please see #msg-61503095 and the embedded links in that post for background info.

The US launch could happen in 2013, pending results of US phase-3 trials.